Melanostatin DM is a research peptide analog of the tripeptide Prolyl-Leucyl-Glycinamide (PLG), designed to study melanocyte-stimulating hormone (α-MSH) receptor modulation. Preclinical studies indicate that it inhibits tyrosinase activity and melanin biosynthesis by influencing MSH-mediated cAMP signaling pathways. Melanostatin DM is used in pigmentation and dermatological peptide research examining melanin regulation and peptide–receptor interactions.
